Study indicates need for developing mucosal vaccines to induce potent immune responses at sites where SARS-CoV-2 infection occurs CIDJournal NIAIDNews FredNatLab SARSCoV2 infection vaccine vaccination mucosal
By Dr. Chinta SidharthanDec 14 2022Reviewed by Danielle Ellis, B.Sc. In a recent study published in Clinical Infectious Diseases, a team of researchers measured the antibodies against severe acute respiratory syndrome coronavirus 2 from nasal fluid, saliva, and plasma to compare the antibody levels between blood and mucosal fluids.
About the study In the present study, the team longitudinally measured the antibody levels in the nasal fluid, saliva, and plasma of individuals infected with SARS-CoV-2 before and after vaccination and vaccinated individuals who had not been infected with SARS-CoV-2. The participants comprised healthcare workers and other employees at the National Institutes of Health in Bethesda, Maryland, in the United States. The study was conducted between April 2020 and February 2022.
Related StoriesIn vaccinated individuals who were not infected with SARS-CoV-2, the anti-spike antibodies in nasal fluid and saliva and the IgA-specific antibodies in the nasal fluid decreased faster than those in plasma. Furthermore, the increase in antibody levels after vaccination in individuals with previous SARS-CoV-2 infections varied across the plasma, saliva, and nasal fluid samples. While one vaccine dose resulted in a 22.
Furthermore, experiments with animal models have shown that intranasal vaccinations against SARS-CoV-2, as well as SARS-CoV-1 and Middle East respiratory syndrome , have been more effective than intramuscular vaccines.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Study finds bebtelovimab therapy lacks efficacy in patients infected with SARS-CoV-2 Omicron subvariantsStudy finds bebtelovimab therapy lacks efficacy in patients infected with SARS-CoV-2 Omicron subvariants medrxivpreprint uarizona VCU SARSCoV2 Omicron coronavirus covid COVID19 antibody
Weiterlesen »
Bioengineered soluble ACE2 for brain protection against SARS-CoV-2 infectionBioengineered soluble ACE2 for brain protection against SARS-CoV-2 infection biorxivpreprint NorthwesternU ChariteBerlin UChicago brain SARSCoV2 ACE2 COVID19 coronavirus covid
Weiterlesen »
Detection of unreported infections based on SARS-CoV-2 antibody seroprevalenceDetection of unreported infections based on SARS-CoV-2 antibody seroprevalence Antibody Coronavirus COVID SARSCoV2 LancetRH_Americ CDCgov QuestDX Labcorp
Weiterlesen »
Research reveals the assembly dynamics of nucleocapsid protein condensates can be regulated by small molecules with therapeutic potentialResearch reveals the assembly dynamics of nucleocapsid protein condensates can be regulated by small molecules with therapeutic potential biorxivpreprint harvardmed Harvard virus coronavirus humancoronaviruses protein nucleocapsidprotein
Weiterlesen »
Study suggests persistent inflammatory response triggered by SARS-CoV-2 may be responsible for observed sequelae in PASC patientsStudy suggests persistent inflammatory response triggered by SARS-CoV-2 may be responsible for observed sequelae in PASC patients biorxivpreprint unidue ChariteBerlin SARSCoV2 inflammation inflammatory covid coronavirus COVID19
Weiterlesen »
The effectiveness of nirmatrelvir-ritonavir and molnupiravir for the treatment of COVID-19 among US veteransThe effectiveness of nirmatrelvir-ritonavir and molnupiravir for the treatment of COVID-19 among US veterans medrxivpreprint OHSUNews YaleMed UMich HopkinsMedicine COVID19 coronavirus covid veterans antiviral
Weiterlesen »